The Chapel Hill Conference on the Nomenclature of Systemic Vasculitis
1. Introduction
The vasculitides comprise a heterogeneous group of diseases characterized by inflammation and destruction of blood vessels. Vessels of any size can be involved which explains the diverse spectrum of clinical diseases attributed to vasculitis. While the immunological basis of disease for vasculitis was recognized over thirty years ago,[1] a standardized classification system was only adopted nearly twenty years later. The initial classification system proposed by the American College of Rheumatology attempted to classify vasculitis according to standardized criteria.[2] The subsequent system described by the Chapel Hill Conference on the Nomenclature of Systemic Vasculitis[3] introduced a system which coupled contemporary commonly used disease names and the size of vessel(s) involved.
|
|
Large Vessel Vasculitis | Giant Cell (Temporal) Arteritis |
Takayasu’s Arterits | |
Medium Sized Vessel Vasculitis | Polyarteritis Nodosa |
Kawasaki’s disease | |
Small Vessel Vasculitis | Wegener’s Granulomatosis* |
Churg Strauss Syndrome* | |
Microscopic Polyangiitis* | |
Henoch Schonlein Purpura | |
Essential Cryoglobulinaemic Vasculitis | |
Cutaneous Leukocytoclastic Angiitis |
1.1. Small vessel vasculitis
Necrotizing arteritis is common to many forms of vasculitis, but involvement of vessels smaller than arteries is unique to small vessel vasculitis.[4] A clinical report of ‘Vasculitis’ originated from the mid-nineteenth century[5] and clinical descriptions of these diseases were published in the 1930s,[6] however it was not until the 1950s that Wegener’s Granulomatosis, Churg Strauss Syndrome and Microscopic polyangiitis were identified as unique clinical entities.[7] In the 1980s it was appreciated that the small vessel vasculitides represented a clinically distinct form of disease.[8] These small vessel vasculitides will be the primary focus of this chapter.
2. Antineutrophil cytoplasmic antibody associated vasculitis
2.1. Background and chapter overview
Glomerulonephritis is a common cause of renal failure both worldwide and in Australia. Rapidly progressive or crescentic glomerulonephritis represents the most severe form of the disease and antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) accounts for >50% and more likely up to 80% of all cases of rapidly progressive glomerulonephritis. The AAVs are considered a heterogenous group of systemic autoimmune conditions characterised by necrotising inflammation of small to medium sized arteries, capillaries and venules. The disease is diagnosed by detecting ANCA in the serum which characteristically is directed against myeloperoxidase (MPO) or proteinase 3 (PR3). The two most severe clinical manifestations of disease are rapidly progressive glomerulonephritis and pulmonary haemorrhage due to pulmonary capillaritis. These syndromes are associated with significant morbidity and untreated have a mortality that approaches 100%. Renal vasculitis occurs in more than 50% of patients at presentation but in 70-85% of patients with AAV during the course of their disease [9]. While current treatments for active ANCA vasculitis are often life-saving they are toxic and more than 1 in 3 patients will suffer a significant treatment related adverse event.[10] A better understanding of the
In the early 1980s two Australian groups based in Melbourne, from St Vincent’s Hospital[11] and the Austin Hospital[12] described the association of antibodies directed against the neutrophil cytoplasm in patients with rapidly progressive glomerulonephritis. These reports represented key advances in our understanding of the pathogenesis of autoimmune small vessel vasculitis. Subsequent work by a Dutch group helped establish the correlation between ANCAs and the three clinical syndromes; Wegener’s granulomatosis, microscopic polyangiits and Churg-Strauss syndrome.[13] More recently these syndromes have been renamed to generate nomenclature free from the use of eponyms.[14-16] The new nomenclature proposed and adopted into the literature and clinical practice in 2011 is as follows; Microscopic Polyangiitis (MPA), Granulomatosis with polyangiitis, (GPA), formally known as Wegener's, Allergic Granulomatosis and Angiitis (AGA) formally known as Churg Strauss Disease and Renal Limited Vasculitis (RLV).[14] This new terminology will be adopted for the remainder of this chapter.
In this chapter, we will concentrate on renal injury resulting from AAV which has formed the basis for clinical and experimental studies. For both MPA and GPA target autoantigens have been identified which are constituents of neutrophils. For MPA, myeloperoxidase (MPO) is usually the target autoantigen, while antibodies to proteinase 3 (PR3) are usually detectable in patients with clinical features of GPA. In both clinical and experimental AAV (GPA or MPA) two separate key steps are required for the development of glomerulonephritis and renal injury. The first critical step involves the development of systemic autoimmunity to the target antigen, MPO or PR3. The second step involves antigen specific nephritogenic immune responses driving glomerular injury and renal disease.
2.2. The development of systemic autoimmunity in MPA and GPA
The development of autoimmunity is a complex process, multifactorial in origin, which involves the loss of tolerance and enhanced cellular and humoral activity.[17] In AAV, disease is defined and characterized by antibodies detected against MPO or PR3. While antibodies form the diagnostic hallmark of disease, cellular immunity is critical and is required for the development of humoral immunity and the subsequent generation of B cells and production of ANCAs. A role for cellular immunity has been defined in both clinical and experimental ANCA vasculitis. In addition to adaptive immune cells, innate immune cells contribute to the generation of autoimmunity with evidence for involvement of different cell types in this disease process.
2.3. The initiation and progression of rapidly progressive glomerulonephritis and renal injury in AAV
Enhanced cellular autoimmunity and innate cells stimulate B cells resulting in the production of antigen specific ANCAs. These auto-antibodies bind to and activate circulating neutrophils. These activated neutrophils are recruited to glomerular capillaries,[18] where they degranulate and initiate renal injury. Degranulating neutrophils release their noxious constituents and also deposit MPO [19] and probably PR3 in the glomerulus. Later, CD4+ T cells recognise the autoantigen (MPO/PR3) in the glomerulus and attract additional immune effector cells; this results in severe renal injury. In both clinical and experimental settings cellular nephritogenic immunity, humoral immunity and innate immune cells are critical for the development of rapidly progressive glomerulonephritis.[20-24] Our current treatment regimes were designed to target these cells, or combinations of them.
In this chapter we will focus on the pathogenesis of the ANCA associated vasculitides, focussing on AAV attributable to MPA and GPA. We will pay attention to the development of autoimmunity and concentrate on end organ injury in the kidney, a critical target of the small vessel vasculitides. Interestingly, while GPA and MPA share many diagnostic and clinical features and patients with these diseases have been grouped together in many clinical trials, more recent evidence including a landmark genetic study, suggests that GPA and MPA represent two different diseases. While we will discuss GPA and MPA separately, there is stronger experimental evidence linking MPO with disease. This includes several small animal studies which have confirmed pathogenic roles for cellular and humoral autoimmunity, directed against MPO, which closely resemble human disease. Our discussion will focus on the disease pathogenesis of AAV and attempt to define future directions for study which ultimately may lead to therapeutic interventions. Information has been made available from human studies assessing mechanisms of disease as well as experimental studies, utilizing rodent models of vasculitis. Further insights into disease pathogenesis can be gained from clinical trials, including those with negative results.
3. Genetic and epigenetic basis of disease in ANCA vasculitis
Consistent with improved mechanistic studies the last decade has witnessed significant advances in our understanding of the role of both the genetic and epigenetic factors driving AAV. While a detailed description and discussion of these factors is beyond the scope of this chapter it would be remiss not to discuss several recent key studies. It is important to note that all results discussed in this section are from clinical studies. It should also be noted that while the varying genetic background of commonly used laboratory rodents may contribute to a particular pattern and severity of disease in experimental AAV, the relevance and correlation of this to human disease is less clear.
A genetic basis for AAV has long been suspected, however this was recently confirmed by a publication which demonstrated a relative risk of 1:56 for first degree relatives of patients with GPA.[25] This rate is similar to that seen in other autoimmune diseases with an established genetic component which contributes to injury. This study followed on from previous studies which had suggested a genetic link into AAV. Many of the candidate genes identified as being over represented in vasculitis patients are associated with genes which encode proteins involved in the immune system. These include several genes encoded in the human leukocyte antigen (HLA) as well as genes encoding protein tyrosine phosphatase non-receptor type 22 (
In a genome wide association study with over 10 000 patients (including controls), not only was a genetic component confirmed but the antigenic specificity for AAV, i.e. for MPO or PR3 was found to have distinct genetic associations. For patients with ANCA directed against PR3, there was a strong genetic association with
An epigenetic basis for disease has also been proposed. Neutrophil levels of the chromatin modification protein complex, H3K27me3, required for gene silencing were decreased in patients with AAV, at both the MPO and PR3 loci. This phenomenon was dependent on the transcription factor encoding gene, RUNX3. Interestingly RUNX3 message was found to be decreased in patients with AAV compared to healthy controls. These studies provided the first evidence that epigenetic modifications present in AAV patients could impair gene silencing and result in aberrant expression of the target auto-antigens, MPO and PR3.[29] These recently published genetic and epigenetic studies have added considerably to our understanding of AAV.
4. Environmental factors driving disease in ANCA vasculitis
In addition to genetic factors, environmental factors contribute to the loss of tolerance, the development of autoimmunity (to MPO or PR3) and subsequent organ injury. Environmental triggers that have been implicated in disease pathogenesis include environmental toxins, pharmacological therapies and infections, for which there is the strongest evidence.
Epidemiological studies have demonstrated increased incidence of ANCA vasculitis, and more specifically MPA, is increased in patients exposed to a variety of environmental toxins,[30] in particular silica.[31] This is thought to result from environmental toxins serving as adjuvants to the immune system.[32] The development of ANCAs, in particular those reactive to MPO, is not uncommon after treatment with propylithiouracil,[33] although systemic disease following treatment is uncommon. Overt MPA with focal necrotising glomerulonephritis has been described in patients treated with penicillamine[34] and hydralazine.[35] The rarity of these phenomena has prevented us from learning more about disease pathogenesis.
Links between infection and ANCA vasculitis have been suggested for some time, with seasonal variation in disease presentation suggesting a correlation with microbial infection.[36] Moreover results from several studies suggested that infection(s) may predate disease initiation and/or relapse in GPA, MPA and pulmonary vasculitis.[37-40] It must be noted that these results are contentious and other studies have not confirmed them.[30] However, nasal colonization with
Several mechanisms have been proposed to link infection with the development of AAV, including the use of complementary proteins, molecular mimicry and the ligation of Toll like receptors (TLRs) which heighten innate and adaptive immune responses as well as activating resident kidney cells. A series of clinical and experimental studies have supported each of these concepts, however it is likely that these mechanisms act, at least partially, in combination.
Molecular mimicry refers to the development of antibodies to host proteins after (repeated) exposure to foreign antigens, this occurs due to structural similarities between host and foreign proteins. Molecular mimicry has been proposed as a reason for the loss of tolerance to self and the subsequent development of autoimmunity.[44] In a series of elegant experiments it was demonstrated that antibodies to the lysosomal associated membrane protein-2 (LAMP-2) were highly prevalent in patients with ANCA vasculitis. Furthermore LAMP-2 was pathogenic and administration of polyclonal LAMP-2 to rodents resulted in a characteristic pattern of AAV, with focal necrotising glomerulonephritis, similar to that observed in human renal vasculitis. We will discuss LAMP-2 in more detail later in this chapter. There is homology between the immunodominant LAMP-2 epitope and the peptide of FimH, which is a component of the fimbriae of Gram negative bacteria. It is hypothesized that certain patients infected with Gram negative bacteria would generate antibodies to LAMP-2 and develop vasculitis, through the process of molecular mimicry.[45] This highly plausible theory provides one explanation for the clinical association between infection and the development of ANCAs or LAMP-2 antibodies.
An earlier study reported that a form of molecular mimicry could link
Both of these studies utilized human samples and elegant rodent models to propose infections as initiators of autoimmunity and renal vasculitis. Further work in this field is required to facilitate a better understanding of how molecular mimicry functions in humans and what organisms could be involved.
Infections activate and ligate Toll-like receptors (TLRs). These receptors are innate pattern and danger recognition receptors, ubiquitously expressed on immune cells, and resident tissue cells. which heighten innate and adaptive immune responses in response to infection or danger signals. Ligation of TLRs after infection can stimulate host immune responses, promoting auto-inflammatory and auto-immune responses. Furthermore TLR ligation can stimulate endothelial cells and other resident kidney cells to generate a cytokine milieu conducive to the recruitment of inflammatory leukocytes.
5. The role of adaptive immunity in the development of ANCA autoimmunity and glomerulonephritis
5.1. The role of humoral immunity in AAV pathogenesis
Since their description in the 1980s antibodies directed against MPO and PR3 have formed the diagnostic hallmark of AAV. While not entirely specific there is a strong association between MPO-ANCA and MPA, while PR3 is commonly associated with GPA. Clinical and experimental studies have supported the notion that ANCA are pathogenic. Furthermore therapies targeting (humoral immunity and) ANCAs, including plasma exchange[47] and the anti-CD20 monoclonal antibody Rituximab,[48-49] have been successful in clinical practice. Most of the experimental evidence has supported a role for MPO in disease, but more recently an animal model of PR3-associated vasculitis has also been developed. This represents a significant advance and it is anticipated that this model will facilitate an improved understanding of the pathogenesis of PR3-AAV. In this section, we will also discuss other roles for B cells including their function as antigen presenting cells (APCs) and as potential regulators of disease.
Are ANCAs pathogenic? There has been increasing evidence supporting a pathogenic role for ANCAs. Results from
Animal studies have demonstrated a pathogenic role for ANCAs. The model described by Xiao et al was one of the first murine models of AAV, which produced severe renal injury. The observed renal injury bore considerable resemblance to that seen in human rapidly progressive glomerulonephritis. In this model MPO deficient mice were immunized with MPO. Subsequently the spleens of these MPO deficient mice were transferred into recombinant activation gene knockout (RAG2-/-) mice, which lack adaptive immunity. After transfer of splenocytes (from MPO immunized MPO-/- mice) RAG2-/- mice developed humoral autoimmunity with the production of MPO-ANCAs. Kidneys from these mice displayed the hallmarks of severe crescentic glomerulonephritis. The authors also performed a passive transfer experiment, administering MPO-ANCAs to RAG2-/- mice. The passive transfer of MPO-ANCA to RAG2-/- mice resulted in a milder form of glomerular injury compared to that seen after splenocyte transfer.[55] These experiments highlighted the pathogenic role for MPO-ANCAs, however, it should be noted that the severe injury occurring after the transfer of splenocytes could reflect cellular immunity contributing to renal injury. None the less, the passive transfer of ANCAs to mice has consistency resulted in a degree of renal injury, which is neutrophil,[56] lipopolysaccharide[57], TLR4[58] and complement [59] dependent.
Additional evidence for a pathogenic role for MPO in driving AAV and renal injury was demonstrated in Wistar-Kyoto rats. Rats developed focal necrotizing glomerulonephritis and pulmonary vasculitis after immunization with purified human MPO. Furthermore a pathogenic role for the chemokine CXCL1 (the rodent homolog of human IL-8) in neutrophil-endothelial interactions was demonstrated, by analysis of neutrophil migration in the capillary beds.[60] Recently Little has described a model of vasculitis, dependent on PR3-ANCA, which develops in mice with a humanised immune system. This model was generated by treating irradiated NOD-scid-IL-2Rγ-/- mice with human haematopoietic cells. In NOD-scid-IL-2Rγ-/- mice there are multiple deficiencies in the function of both innate and adaptive immune cells. These chimeric mice were then treated with human immunoglobulin from patients with PR3-ANCA vasculitis or control serum. In control treated mice no glomerular injury was observed, however mice treated with PR3-ANCA demonstrated (at least mild) glomerulonephritis, while more severe injury was observed in 17% of PR3-ANCA treated mice.[61] While further work is required to confirm that this murine model is robust, it is anticipated that it will provide a good basis to explore the pathogenic nature of PR3-ANCA in clinical practice.
Another potential antigenic target is LAMP-2. Antibodies to LAMP-2 were reliably detected in more than 90% of patients with active ANCA associated necrotising crescentic glomerulonephritis. LAMP-2 antibodies were detected even when MPO-ANCA and PR3-ANCA could not be detected, suggesting this test may have improved diagnostic sensitivity and could possibly be useful for serological diagnosis in patients with renal limited vasculitis, who traditionally are found to be ANCA negative. Antibodies to LAMP-2 were also pathogenic and administration of human LAMP-2 antibodies to Wistar Kyoto rats resulted in pauci-immune focal necrotizing glomerulonephritis.[45] Subsequently, the authors working with several collaborative groups, have verified the prevalence of antibodies to LAMP-2 in cohorts of ANCA patients from a range of European countries. Three different techniques; enzyme linked immunosorbent assay; western blotting and an indirect immunofluorescence assay were all readily able to detect antibodies. Interestingly antibodies were undetectable shortly after treatment, although they were detectable during clinical relapse, highlighting the potential usefulness of these antibodies in clinical practice.[62] However studies from the United States could not confirm these findings, where the sensitivity of detecting LAMP-2 antibodies was much lower than that seen within the European studies.[63] The divergence of results is interesting and suggests that further work is required to facilitate assays which could result in the development of better diagnostic tools.
Most studies examining the pathogenic role of B cells in AAV have focussed on their role as effector cells, however B cells have a more diverse range of functions than autoantibody production alone. In other scenarios B cells are considered antigen presenting cells, while they possibly influence T cell responses.[64]
The B cell activating factor (BAFF) has also been shown to be elevated in patients with AAV,[65] which is exciting considering the therapeutic promise shown with BAFF inhibitors in systemic lupus erythematosus (SLE).[66] B cells may also contribute to disease in other ways and a detailed analysis of renal biopsies from patients with AAV demonstrated significant B cell infiltration, including organized B cell clusters.[67] In addition to pro-inflammatory responses B cell also display regulatory function and produce IL-10, a regulatory cytokine. Interestingly in patients with SLE regulatory B cells (Bregs) are impaired and are unable to suppress effector T cells.[68] While this has not been explored to date in vasculitis, it remains possible that heightened humoral and cellular immunity occurs as a consequence of impaired Bregs.
In concluding, B cells form the diagnostic hallmarks of ANCA vasculitis and are pathogenic. The success observed in clinical practice with therapies which chiefly target B cells has not been fully elucidated and may extend beyond autoantibody inhibition. Interestingly, Rituximab was shown to treat the clinical symptoms of GPA, even when ANCAs were not detectable.[69] An in-depth understanding of the role of humoral immunity is awaited and may help direct future therapies.
5.2. The role of cellular immunity in AAV pathogenesis
While ANCAs are diagnostic and pathogenic in AAV, cellular immunity is an essential requirement for the initiation and continued production of auto-reactive B cell responses and for driving effector cell responses in the kidney. Evidence for a key role for cellular autoimmunity in AAV comes from several lines of evidence, including observational studies in humans, reports of refractory disease responding to treatments targeting T cells and extensive murine studies showing a pathogenic role for T cells in the development of autoimmunity. Vasculitis involving the glomerular capillary bed has little or no antibody deposition, but rather demonstrates delayed type hypersensitivity responses, including fibrin deposition. This is most likely to be a consequence of auto-reactive CD4+ effector cells recognizing MPO, which is present in glomeruli in both human and experimental ANCA vasculitis [70-72]. In addition to enhancing inflammation, regulatory T cells (Tregs) are likely to have an important role in modulating immune responses and glomerular injury.
T cells are active participants in the loss of tolerance and the development of autoimmunity in AAV. Firstly we know that ANCAs are class switched high affinity antibodies which are (therefore) dependent on T cells for their generation.[73] Secondly, in proliferation studies, it has been demonstrated that auto-reactive T cells from patents with AAV respond to MPO and PR3,[74] while markers of T cell activity are increased in parallel with disease activity.[75-76] Furthermore, in renal biopsy samples from patients with AAV, the number of infiltrating T cells correlates with the severity of injury. Additional evidence supporting a pathogenic role for T cells was provided when 15 patients with refractory vasculitis, resistant to other therapies, were successfully treated with anti-thymocyte globulin, which targets T cells.[77]
Early studies supported a role for T helper (Th) 1 (and possibly Th2) cells in the pathogenesis of AAV. Peripheral blood lymphocytes from patients with MPO-ANCA were shown to produce IFNγ when stimulated.[78] The more recently defined Th17 cells represent a distinct lineage of CD4+ T cells, which are characterized by the production of IL-17A.[79] Two key human studies supported a role for Th17 cells in ANCA vasculitis. Firstly it was demonstrated that when peripheral blood from GPA patients was stimulated with PR3, there was an increased percentage of IL-17A producing CD4+ T cells (Th17). After stimulation no difference in IFNγ production was seen, suggesting that Th1 cells were not involved. The authors proposed that this skewed Th17 response supported a role for Th17 cells in disease.[80] A subsequent study demonstrated that sera from patients with active AAV consistently displayed a Th17 phenotype. Cytokines associated with Th17 cells, including IL-17A and IL-23, were increased in patients with acute AAV, while levels of IFNγ were unchanged. Interestingly immunosuppressive therapy did not consistently decrease IL-23 or IL-17 production.[23] In a study of human ANCA biopsies it has been shown that IL-17A producing CD4+ T cells constitute part of the inflammatory infiltrate and correspond with disease severity.[81] In addition, murine models have provided strong evidence for a pathogenic role for CD4+ T cells in glomerulonephritis.
An MPO-dependent murine model which demonstrates considerable homology to human ANCA vasculitis, where mice develop autoimmunity to MPO and focal necrotising glomerulonephritis was described. Immunization of C57BL/6 wild type mice with MPO results in cellular and humoral autoimmunity to MPO. A small dose of sheep anti-mouse glomerular basement membrane serum is subsequently administered. Treatment of chicken ovalbumin (OVA) immunized mice with this dose of sheep anti-mouse glomerular basement membrane serum does not result in significant renal injury. However in mice immunized with MPO and then sheep anti-mouse glomerular basement membrane serum significant renal injury is seen. Depletion of CD4+ effector cells significantly attenuated glomerular injury in this model, while experiments performed in B cell-deficient mice did not show renal protection.[72] These results provide strong evidence for a pathogenic role for CD4+ effector cells contributing to rapidly progressive glomerulonephritis in MPO-ANCA vasculitis. Subsequent work from this group has supported a role for both Th1 and Th17 cells in disease. Firstly, using IL-17A-/- mice it was shown that the development of cellular autoimmunity and necrotizing glomerulonephritis was IL-17A dependent. Secondly in the absence of IL-17A there was a decrease in glomerular neutrophil and macrophage recruitment and renal injury was attenuated. These results highlight the potential therapeutic benefits of IL-17A blockade in AAV.[24] This group has also elucidated that both IL-17A and IFNγ can drive nephritogenic autoimmunity and renal injury in AAV. Interestingly ligation of different TLRs dictated the pattern of cytokine production, TLR2 ligation promoted the development of Th17 autoimmunity, while TLR9 ligation drove Th1 autoimmunity. Mice which developed Th17 induced renal injury were successfully treated with anti-IL-17A monoclonal antibody (mAb). Conversely in mice that developed predominant Th1 driven injury, administration of anti-IFNγ mAb attenuated renal injury.[82] Work from Richard Kitching’s group has further refined our understanding of the role of CD4+ T cells in the pathogenesis of AAV. Using 20 amino acid sequence peptides they identified the immunodominant MPO CD4+ T cell epitope. Subsequently they produced T cell clones which were specific for this immunodominant MPO epitope, which were then injected into mice. Using three different techniques it was demonstrated that when the MPO peptide (or whole MPO) was deposited in glomeruli focal necrotising glomerulonephritis was driven by antigen specific CD4+ T cells.[83] These key studies have helped define how effector T cells drive glomerular injury.
6. The role of Th17 cells in autoimmunity and glomerulonephritis
The original description of Th1, IFNγ producing and Th2, IL-4 producing, T helper cells by Mosmann and Coffman [84] has been expanded to include a new subset of Th cells, the IL-17A producing Th17 cells.[79, 85-86] While the prototypic cytokine produced by Th17 cells is IL-17A, these cells produce numerous other cytokines, including the ubiquitous IL-6, TNF and IL-1β.[85] Two transcription factors are critical for the development of Th17 cells; STAT3 and Rorγt.[87-88] For the induction and maintenance Th17 cells, several cytokines are required, these include; IL-23,[89] IL-6, TGF-β,[90-93] while IL-21 is required for amplification of Th17 cells.[94-96]
Prior to the discovery of Th17 cells, autoimmunity was believed to be predominantly a Th1-mediated phenomenon. There were inconsistencies, however, in this paradigm, for example IFNγ-/- mice developed exaggerated organ inflammation and injury in experimental autoimmune models.[97-98] Subsequently it was demonstrated that organ injury (in the most common autoimmune model, experimental autoimmune encephalomyelitis [EAE]) was unchanged in IL-12p35-/- mice (functionally Th1 deficient), while injury was significantly attenuated in IL-12p40-/- (functionally Th1 and Th17 deficient) and IL-12p19-/- (functionally Th17 deficient) mice.[99] Similarly IL-17A-/- mice were protected from EAE, [100] while increased IL-17 expression was seen in patients with multiple sclerosis, [101] a common autoimmune disease seen in clinical practice, which is the human equivalent of EAE. Further studies have implicated Th17 cells in several autoimmune diseases including rheumatoid arthritis,[102] consistent with this finding IL-17A-/- mice are protected from murine experimental arthritis.[103-104] IL-17A has been implicated in inflammatory bowel disease, both experimental[105] and clinical[106] as well as human inflammatory skin conditions.[107-108]
7. Th17 cells in the kidney
Early studies performed in gene deficient mice supported a role for Th17 related cytokines in the development of experimental autoimmune glomerulonephritis[109] and sheep anti-mouse glomerular basement membrane disease.[110] A pathogenic role for RORγt, the key IL-17A transcription factor, was also demonstrated in a murine model of crescentic glomerulonephritis.[111] A direct role for Th17 cells acting as effectors was subsequently published. The antigen, ovalbumin (OVA), was planted in the kidneys of RAG1-/- mice, after the conjugation of OVA to a non-nephritogenic antibody specific for the glomerular basement membrane. This was followed by the administration of Th-17 polarized ovalbumin specific CD4+ T cells, which resulted in neutrophil mediated proliferative glomerulonephritis.[112] Detailed reviews of the role of Th17 cells in kidney disease have recently been published.[113-114]
Th17 cells are a distinct line of CD4+ T helper cells with unique transcription factors and effector cytokines. These cells are active participants in the development of autoimmunity but are also involved as effector cells in autoimmune conditions including rapidly progressive glomerulonephritis.
In addition to CD4+ effector T cells other T cells are likely to contribute to AAV. Several years ago it was demonstrated that CD4+ effector memory cells (Tem) were increased in the blood of GPA patients in remission, compared to those with active disease.[115] While Tem were decreased in the blood, they were increased in the urine of patients with active disease -suggesting that these cells may influence renal injury during active disease.[116] Further
Regulatory T cells (Tregs) represent a subset of CD4+ CD25+ T cells which perform a key role in regulating inflammation and tissue injury. These cells are identified through the expression of FoxP3, which is considered a master regulator of Tregs. In several autoimmune diseases, including Goodpasture’s disease, Tregs are required for the maintenance of tolerance and loss of Treg function can result in the development of autoimmunity and organ injury.[119] In GPA clinical studies have shown that although circulating FoxP3-expressing Tregs vary in number their suppressive capacity is reduced.[120] In MPA patients (and experimentally) FoxP3-expressing Tregs display diminished capacity to suppress antigen specific MPO responses an effect mediated through tryptophan.[121] Our current understanding of the role of Tregs in AAV is limited and further studies are required to improve our knowledge of their role in disease pathogenesis in order to facilitate treatments aimed at optimizing their therapeutic potential. It is well known that Th17 cells and Tregs require many of the same cytokines for growth and development and it has been postulated that they have an inverse relationship. Whilst this explanation may be simplistic it is attractive to hypothesise that both the initiation of disease and flares seen in AAV could be attributed to an imbalance in the Th17: Treg ratio; with Th17 overactivity promoting disease. This imbalance could be targeted in future treatment protocols.
8. Innate immune responses in ANCA associated vasculitis
8.1. Neutrophils, key effector cells, in ANCA associated vasculitis
Neutrophils play a critical role in the pathogenesis of ANCA vasculitis. Not only are neutrophils the primary effector cells in the kidney but neutrophils also contain the target auto-antigens, MPO, PR3 (and LAMP-2) and hence are directly involved in the auto-immune process. We will discuss three different aspects of neutrophil involvement in disease, (a) The role of the Neutrophil in the development of Autoimmunity, (b) Neutrophil Activation by ANCAs and (c) Neutrophil Endothelial Interactions, which initiate glomerular injury.
8.1.1. The role of the neutrophil in the development of autoimmunity
It is well established that ANCAs bind to the autoantigens, MPO or PR3, located on the cell surface of the neutrophil. How and why these autoantigens translocate to the cell surface is poorly understood. We know that neutrophils die through apoptosis or necrosis and data suggests that neutrophil death through apoptosis can promote the loss of tolerance to MPO or PR3. After cell death neutrophils release granule constituents, including MPO and PR3, which translocate to the cell surface[122-123] where they serve as antigenic targets. This phenomenon was thought to occur exclusively after neutrophil death through apoptosis, which is possibly related to a slower mechanism of cell death, although the operational mechanisms of this system require further clarification.
An additional pathway linking neutrophil cell death and autoimmunity has recently been proposed, involving a distinct method of neutrophil death involving neutrophil extracellular traps (NETs). Neutrophils extrude NETs which consist of chromatin structures and include anti-microbial peptides such as; MPO, PR3 elastin, cathepsin, and lactoferrin.[124] Dying neutrophils extrude NETs to kill invading pathogens in a process recently named NETosis. It is understood that neutrophils, through NETosis, contribute to the development of autoimmunity, a concept well established in SLE. In SLE, in response to chronic autoantibody stimulation neutrophils and their NETs activate plasmacytoid dendritic cells which secrete IFNα.[125-127] NETosis has been linked with glomerular injury in AAV, through the enhancement of endothelial-leukocyte interaction,[71] however only recently have NETs been implicated in the development of ANCA autoimmunity. NETotic neutrophils interacted with myeloid dendritic cells (mDC). This interaction was not observed when neutrophils died by necrosis or apoptosis. This process was dependent on both TNF and IFNγ and in their absence NETosis did not occur. The interaction between the NETotic neutrophil and the mDC resulted in the transfer of MPO and PR3 to the mDC, which potentially could induce and promote adaptive immune responses. This process was confirmed to be pathogenic
While neutrophil apoptosis and NETosis provide some insight into the role of the neutrophil in the development of AAV, there remain several ‘gaps’ in our knowledge. Why AAV patients develop autoimmunity to MPO/PR3, with an associated clinical syndrome and yet they do not develop autoantibodies to other neutrophil constituents which are released after cell death is unclear. The driving factors behind apoptosis and NETosis have not been well established. Further studies in this area are required before definitive conclusions can be reached. In addition to promoting autoimmunity the ANCA-neutrophil interaction is a key to two other mechanisms of injury, ANCA binding to neutrophils leading to neutrophil activation and an oxidative burst, and the recruitment of ANCA bound neutrophils to the glomerulus where they initiate renal injury.
8.1.2. Neutrophil activation by ANCAs
The first paper suggesting a role for ANCA in activating neutrophils was published over 20 years ago. In this landmark paper it was shown that both MPO-ANCA and PR3-ANCA could bind to primed neutrophils. After neutrophil priming by tumour necrosis factor (TNF) MPO and PR3 were translocated to the cell surface, providing an autoantibody antigenic target. Neutrophil binding by ANCAs produced an oxidative burst and resulted in degranulation.[115] Other authors have confirmed this process and shown that it is also Fcgamma RII-dependent.[129] Cytokine priming of neutrophils is important for ANCA binding as it increases surface expression of the autoantigens and mobilizes the NADPH oxidase complex, further increasing ANCA binding.[27, 53] In addition to TNF, IL-18 and granulocyte macrophage colony stimulating factor can prime neutrophils and enhance ANCA binding.[52]
The pathogenic role of TNF in AAV has attracted significant interest both experimentally and clinically. In a passive transfer model of MPO-ANCA vasculitis pre-treatment with lipopolysaccharide (LPS) increased systemic inflammation and glomerular injury. The
The intracellular signalling pathways activated by ANCA neutrophil binding are multiple, although several pathways are shared. Whereas the Fc portion of ANCA IgG activates tyrosine kinase pathways,[137] the F(ab’)2 portion activates a G protein pathway.[138] Despite initiating two separate pathways, these pathways converge on the p21ras GTPase, which is essential for many neutrophil functions.[139] The identification of these pathways, combined with the development of antibodies directed against specific components of these pathways, predominantly used in preclinical models, has increased expectations of their potential therapeutic use in autoimmune diseases including renal vasculitis.[140-141]
8.1.3. Neutrophil- endothelial interactions
The interaction between neutrophils and endothelial cells is important in the initiation of glomerular lesions, including fibrinoid necrosis, which is frequently observed in patients with renal vasculitis. Under normal physiological conditions neutrophils do not interact with the endothelium, however when the endothelium is activated resulting in increased expression of adhesion molecules and chemokines (and neutrophils are activated) neutrophil recruitment, binding and transmigration is increased. Our understanding of this complex dynamic has been improved through the use of in vitro systems, which include flow chambers mimicking blood flow in human capillaries. For these studies neutrophils from healthy controls and patients with AAV have been compared. Further information has been gleaned from experimental models using live imaging of the kidney, including intravital microscopy.
It is likely that TNF production and complement activation in AAV patients results in a persistent low grade activation of neutrophils.[142] Results from in vitro studies have shown that neutrophils exposed to ANCA bind to human umbilical vein endothelial cells (HUVECs),[143-144] with up-regulation of CD11b, an adhesion molecule.[145-146] In a flow system set up to mirror blood flow in human capillaries, ANCA treated neutrophils demonstrated increased adhesion and transmigration which was β2 integrin and CXCR2 (neutrophil cell surface receptors) dependent.[146] This is likely to resemble what happens in human AAV, where expression of both β1 and β2 integrins are increased in circulating neutrophils,[147] and the adhesion molecules ICAM and VCAM are expressed on glomerular endothelial cells.[148] Additional results from human studies have implicated IL-8 in leukocyte recruitment which was also shown to correlate with glomerular injury.[51] Neutrophil degranulation with the accompanying release of reactive oxygen species, proteases[149-150] and an oxidative burst[151-152] directly leads to endothelial injury. Evidence for enhanced endothelial injury includes increased levels of endothelial cell microparticles in active disease, which subsequently reduce when the disease remits.[153-154] This is in direct contrast to the restorative endothelial progenitor cells which are decreased when disease is active.[155-156] It has been suggested that the pro-angiogenic protein, angiopoietin-2, may act locally to promote inflammation and endothelial cell injury.[154] It is likely that several mechanisms combine to result in endothelial injury. We know that neutrophil degranulation also results in deposition of the neutrophil constituents, MPO and PR3 in the glomerular bed,[157] and these deposited autoantigens provide targets for antigen specific T and B cells, which recruit additional effector cells, promoting a vicious cycle of injury.
Many of the original studies assessing neutrophil recruitment to the capillaries used intravital imaging of mesenteric and cremasteric vessels. These vessels are more accessible and provide some parallels with leukocyte recruitment seen in renal and lung vasculitis. More recently Michael Hickey’s group have pioneered new methods for assessing neutrophil physiology in the inflamed glomerulus, which has considerably improved our understanding of leukocyte behaviour in glomerulonephritis.[158-159].
In vitro studies performed in a flow chamber have shown that human neutrophils treated with ANCA display altered patterns of rolling, adhesion and transmigration.[146, 160] Using intravital microscopy to visualise mesenteric postcapillary venules Little et al found that administration of MPO-ANCA induced neutrophil adhesion and transmigration. Similarly studies using intravital microscopy to visualize murine cremasteric postcapillary venules demonstrated increased neutrophil adhesion and transmigration after the passive transfer of MPO-ANCA. Neutrophil recruitment was both Fcgamma receptor and β2 integrin dependent.[161] While these studies provided valuable insight into neutrophil recruitment and transmigration in inflamed tissues in AAV, it remained unclear if the observations seen in the postcapillary venules could be replicated in the glomerulus. The use of live imaging of the murine kidney has facilitated the study of leukocyte behaviour in models of glomerular injury. Differences in neutrophil behaviour in the inflamed glomerulus have been noted. In the heterologous phase of renal injury induced after administration of sheep anti-mouse GBM serum, neutrophil recruitment occurred via rapid arrest and occurred in the absence of rolling.[158] Relevant to AAV, in mice treated with LPS and MPO-ANCA glomerular neutrophil recruitment occurred in a lymphocyte function-associated antigen (LFA-1)(a leukocyte integrin) dependent manner. However if an increased dose of MPO-ANCA was used (without LPS priming), neutrophil recruitment was α4-integrin dependent, but β2-integrin independent.[18] These studies highlight how MPO-ANCA can induce glomerular neutrophil recruitment through many different pathways and furthermore demonstrate that the glomerulus is a unique organ in which neutrophil migration differs from other postcapillary venules. While it is likely that injury in humans with renal vasculitis is a consequence of several mechanisms (discussed above) acting in tandem, direct visualization of the kidney appears to be the best technique to assess glomerulonephritis. In addition to the mechanisms detailed above there are likely to be several other factors which contribute to pathogenic neutrophil-endothelial interaction and the ensuing rapidly progressive glomerulonephritis, several of these are discussed later in this chapter.
8.1.3.1. The role of NETs in neutrophil-endothelial interactions and glomerulonephritis in AAV
The role of neutrophil extracellular traps (NETs) in the development of autoimmunity to MPO and PR3 has been discussed earlier. A further role for NETs in driving effector responses in renal vasculitis was described in an innovative paper published in 2009. In this manuscript, Kessenbrock et al, found that primed neutrophils cultured with ANCAs resulted in the development of NETs and these chromatin fibres contained the auto-antigens MPO and PR3. When neutrophils were recruited to inflamed glomeruli, degranulation of the neutrophil and NETs resulted in the deposition of these autoantigens in the glomerulus. Furthermore they demonstrated that in human kidney biopsies, from patients with AAV, NET formation was associated with areas of high neutrophil influx and acute injury.[71] It is likely that deposition of MPO and PR3 could directly result in glomerular injury, however these autoantigens could also serve as targets for auto-reactive CD4+ T cells and B cells further increasing the influx of inflammatory cells and exacerbating glomerular injury.
8.1.3.2. A pathogenic role for neutrophil microparticles in AAV
Microparticles in neutrophils contain an abundance of adhesion molecules and proteases which include the ANCA auto-antigens PR3 and MPO.[162] Recent data has shown ANCAs can induce the release of neutrophil microparticles from primed neutrophils. These microparticles bind to endothelial cells through an up-regulation of adhesion molecules and result in increased endothelial reactive oxygen species and released pro-inflammatory cytokines including, IL-6 and IL-8. The clinical relevance of this was supported by data which demonstrated that neutrophil microparticles were more readily detected in patients (children) with active AAV, while levels were suppressed in healthy controls and patients with inactive disease.[163] Several other mechanisms of neutrophil microparticle release have been described, including those triggered by the complement system, which is also active in renal vasculitis. These studies further highlight the complex nature of neutrophil induced glomerular injury in renal vasculitis. It is likely that that the synchrony of many innate immune cells and adaptive immunity result in the severe injury observed in rapidly progressive glomerulonephritis and acute kidney injury.
8.2. The role of Toll Like Receptors (TLRs) in ANCA associated vasculitis
The innate pattern recognition receptors, TLRs, recognise molecular patterns commonly found in bacterial and viral organisms.[164] In response to invading microbes, TLR ligation results in a ‘hard-wired’ activation of the innate immune system and heightened adaptive immune responses. While TLRs are required for protection from invading microbes, inappropriate stimulation can result in the development of autoimmunity and organ injury,[165] including renal disease.[166] In several experimental models of kidney disease, including acute kidney injury,[167] lupus nephritis[168] and crescentic glomerulonephritis,[169] we and others have demonstrated pathogenic roles for TLRs. However their role in AAV is likely to be dual. Firstly ligation of TLRs heightens innate and adaptive immune response, which in turn leads to the loss of tolerance and the development of autoimmunity. Secondly, TLRs activate both effector cells and resident kidney cells, increasing glomerular inflammation and renal injury. This is important as infections are known to promote injury in AAV, with TLRs providing a link between infection and the development of AAV and disease relapses. While many TLRs have been implicated in autoimmunity studies in AAV have largely concentrated on the surface receptors, TLR2 and TLR4, as well as the intracellular TLR9.
There is clinical evidence implicating TLRs in the loss of tolerance in AAV. Stimulation of peripheral blood mononuclear cells (PBMCs) from GPA patients with a TLR9 ligand resulted in increased ANCA production.[170] Moreover in patients with AAV in remission TLR9 expression is increased on B lymphocytes and when these B lymphocytes were cultured with a TLR9 ligand they produced ANCA.[171] These studies support a role for infection (through ligation of TLR9) promoting humoral autoimmunity. Expression of TLR2, TLR4 and TLR9 on B lymphocytes, T lymphocytes, natural killer (NK) cells, monocytes and granulocytes from AAV patients (and controls) was assessed. Amongst AAV patient’s monocytes and NK cells had increased TLR expression.[172] We have provided supporting evidence for a pathogenic role for TLRs using experimental models of AAV. Immunization of WT mice with a TLR ligand and MPO resulted in the loss of tolerance with the development of cellular and humoral autoimmune responses and later necrotising glomerulonephritis. Interestingly immunization with a TLR9 ligand and MPO resulted in T-bet dependent IFNγ production and macrophage mediated renal injury. Conversely autoimmunity induced by a TLR2 ligand and MPO resulted in ROR-γ dependent Th17 autoimmunity and neutrophil mediated renal injury.[82]
However, TLRs are also likely to be involved in effector responses. While TLRs are expressed at low and often undetectable levels in normal kidney biopsies, increased expression has been seen in glomerulonephritis. In lupus nephritis glomerular and tubular TLR9 expression was shown to be increased in both children and adults.[173-174] In studies assessing patterns of TLR2, TLR4 and TLR9 in glomerulonephritis, strong TLR2 and TLR4 staining was seen in the inflammatory infiltrates of patients with AAV.[175] We have stained renal biopsies from patients with AAV and found that TLR9 staining is positive in the glomeruli (unpublished data), as illustrated.
Further studies have supported an interaction between AAV and TLRs, when epithelial cells, from kidney and lung, primed with PR3-ANCA serum produced exaggerated cytokine levels after TLR stimulation.[176] While early studies suggested that lipopolysaccharide (LPS) enhanced effector responses in AAV,[57] our understanding of this process has increased. We demonstrated that highly purified LPS, a pure TLR4 ligand, increased neutrophil recruitment and glomerular injury after the passive transfer of MPO-ANCA, in a TLR4 dependent manner. We used bone marrow chimeras to define the relative contributions of bone marrow cell TLR4 and intrinsic renal cell TLR4 to the disease process. We found that both bone marrow and resident kidney cell TLR4 were required for maximal neutrophil recruitment and renal injury.[58] These studies highlighted the importance of TLR4 (and potentially other TLRs) in driving effector responses in ANCA vasculitis.
8.3. The role of complement in ANCA associated vasculitis
The complement system is recognized as one of the phylogenetically oldest components of human immune defence. This highly regulated system of proteins (together with their regulatory inhibitors) compromise an important part of host defence. In response to either innate or adaptive stimuli activation of the complement system results in a cascade of amplification and cleavage steps with the generation of anaphylatoxins (C5a and C3a) and a terminal attack complex capable of lying cells.[177] Three complement pathways are well described, namely, the classical pathway, the alternate pathway which is initiated by recognition of foreign surfaces and the mannose binding lectin pathway.[178] More recently a pathway which is initiated by coagulation and fibrinolytic proteins has been described.[179] In addition to its role in host defence, activation of the complement cascade can result in tissue injury and has been implicated in many forms of glomerulonephritis and kidney injury. Traditionally complement was not considered critical to the pathogenesis of AAV as renal injury was considered ‘pauci immune’ in nature and hence free from complement (and immune complex) deposition. Interestingly complement is frequently observed in renal and skin biopsies from patients with AAV,[180-182] while in vitro studies have demonstrated a role for complement in ANCA-neutrophil interactions.
From historical data we know that when neutrophils are activated by ANCA, the complement cascade is triggered and C3a is produced.[183] We also know that priming neutrophils with C5a enhances ANCA-neutrophil interactions,[184] an effect mediated by p38 mitogen-activated protein kinase, extracellular signal-regulated kinase and phosphoinositol 3-kinase.[185] Results from clinical studies have shown that serum and urine levels of C5a are elevated in patients with active disease strongly supporting the notion that the complement cascade is activated in active AAV.[186] Strong support for a pathogenic role for complement has also been provided from experimental studies. In an extensive set of experiments, the North Carolina group robustly demonstrated that complement depletion (achieved through the use of cobra venom serum) abrogated disease, an effect mediated through C5 and Factor B.[183] Factor B is critical for alternative pathway activation. Similarly inhibition of C5 using a mAb successfully attenuated experimental anti-MPO induced glomerulonephritis.[59] These studies detailing a pathogenic role for the alternative pathway in ANCA induced glomerulonephritis have helped improve our understanding of the disease. More recently a mAb directed against C5, Eculuzimab (also known as Soliris and manufactured by Alexion Pharmaceuticals) has been licensed for the treatment of several complement mediated diseases, including paroxysmal nocturnal hemoglobinuria. There is growing interest that C5 inhibition could be used for the treatment of glomerulonephritis and organ injury induced by AAV and this has formed the basis of a clinical trial currently underway in the United States.
8.4. Dendritic cells as antigen presenting cells and effector cells in AAV
Evidence from experimental models has supported a role for dendritic cells (DCs) in initiating and promoting immune responses in autoimmune diseases.[187] These specialised antigen presenting cells (APCs) recognise antigens through pattern-recognition receptors and co-ordinate the initiation and maintenance of the immune response.[188] Little is currently known about antigen presentation and the subsequent development of autoimmunity in AAV. It is likely that DCs are involved in two processes, firstly in the development of autoimmunity through interaction with dying neutrophils and also, acting locally, promoting kidney injury where their presence in renal biopsy samples positively correlates with injury.
A pathogenic role for DCs in human AAV was recognised several years ago. When immature DCs were isolated from GPA patients and cultured with PR3, markers of DC activation, CD80 and CD86 were increased. These antigen primed DCs were able to produce IFNγ, consistent with a Th1 phenotype.[189] In an experimental model of MPO induced ANCA vasculitis, we have shown that pulsing DCs with MPO is an effective means of inducing cellular and humoral autoimmunity directed against MPO. Furthermore, using our murine model of focal necrotising glomerulonephritis, these mice developed severe functional and histological renal injury (unpublished data). It is likely that up-regulation of DCs is (at least partially) TLR mediated and in AAV this could result from infection. After immunizing WT mice with a TLR2 or TLR9 ligand and MPO we found an increase in DC maturation (assessed as an increase in CD86 expression), compared to mice immunized with MPO alone.[82] In additional unpublished work, pilot studies have shown that stimulation of DCs with a TLR9 ligand and MPO results in increased CD40, CD80 and CD86 expression, compared to DCs stimulated with MPO alone, this is demonstrated below. These clinical and experimental studies implicate DCs in the loss of tolerance to MPO.
A limitation of both the clinical and experimental studies is that these studies have largely focussed on myeloid DCs and not plasmacytoid DCs. In other diseases, including systemic lupus erythematosus, plasmacytoid DCs have been shown to be potent inducers of Type 1 IFNs and drive the development of autoimmunity.[190] In addition to their role in the development of autoimmune responses DCs represent a component of the characteristic inflammatory infiltrate see on renal biopsy samples from patients with AAV. Increased numbers of immature (CD209+) and mature (CD208+) DCs were found in renal biopsies from patients with AAV.[191] While these studies do not prove that DCs are pathogenic in renal vasculitis, their association with the inflammatory infiltrate suggests that they may be involved in the promotion of renal inflammation and injury.
9. The role of resident kidney cells in ANCA associated renal vasculitis
Results from many of the studies discussed above have demonstrated that he kidney is not an ‘innocent bystander’ in the disease process. Rather the kidney provides an anatomic and physiological milieu which is well suited to recruit inflammatory cells. In our studies we have found that TLR ligation increased ANCA induced glomerular neutrophil recruitment and injury, which required contributions from both bone marrow and resident kidney cells.[58] Our studies strongly supported a role for glomerular endothelial cells in this disease process and the role of the endothelium in promoting inflammation and injury is well known. It is likely that other glomerular cell types contribute to injury and immunofluorescent staining of kidney biopsies from patients with AAV has demonstrated that podocytes and tubulo-interstitial cells are major producers of IL-18, which is involved in neutrophil recruitment.[52] Similarly after staining human biopsies from AAV patients with crescentic glomerulonephritis the pathogenic isoform of the stress response protein kinase p38MAPK was detected in the podocyte, further implicating the role of this specialised cell in driving glomerular injury.[192] In addition to the glomerular injury observed in ANCA associated renal vasculitis tubular lesions, most notably peritubular inflammatory capillaritis, are common and are associated with a poor prognosis.[193] The interstitium is a prime target for inflammatory cells as many of the tubular epithelial cells express MHCII, TLRs and complement receptors, with which they can interact.[194] Furthermore peritubular capillaries display physiological characteristics similar to postcapillary venules which further increases the recruitment of inflammatory cells commonly observed in crescentic glomerulonephritis.[195-196] In conclusion it is apparent that the kidney harbours a particular environment which facilitates the recruitment of inflammatory cells and subsequent renal injury making it the key target for injury in AAV.
10. Conclusions
As new concepts of autoimmunity and cellular functions are elucidated in both innate and humoral immunity our scope of understanding of this complex disease entity continues to expand. Whilst an appreciation of the involvement of the adaptive immune dysfunction that contributes to AAV is well established new and varied innate immune system mechanisms of pathogenesis are emerging. Recent work investigating neutrophil functions and life cycle including the newly identified and described NETosis, along with imaging modalities allowing accurate characterisation of neutrophil trafficking and interactions with endothelial cells of the vessel wall provide us with a better understanding of the important role these cells have to play in this multifactorial disease process. The huge range of new biologic agents and advancing therapeutic technologies bring with them the possibilities of more effective, targeted, less toxic therapies for our patients.
References
- 1.
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med.Fauci A. S Haynes B Katz P 1978 Nov;89(5 Pt 1):660-76. - 2.
Jr., Masi AT, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum.Hunder G. G Arend W. P Bloch D. A Calabrese L. H Fauci A. S Fries J. F Leavitt R. Y Lie J. T Lightfoot R. W 1990 Aug;33 8 1065 7 - 3.
Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum.Jennette J. C Falk R. J Andrassy K Bacon P. A Churg J Gross W. L Hagen E. C Hoffman G. S Hunder G. G Kallenberg C. G et al 1994 Feb;37 2 187 92 - 4.
Small-vessel vasculitis. N Engl J Med.Jennette J. C Falk R. J 1997 Nov 20;337 21 1512 23 - 5.
Ueber eine bisher nicht beschreibene eigenthümliche Arterienerkrankung (Periarteriitis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med.Kussmaul A Maier R 1866 1 484 518 - 6.
Grenzformen der Periarteriitis nodosa Frankf Z Pathol.Klinger H 1931 42 455 80 - 7.
Wegener’s granulomatosis: pathology and review of the literature. AMA Arch Pathol.Godman G. C Churg J 1954 Dec;58 6 533 53 - 8.
Classification of the necrotizing vasculitides in man.. Clin Rheum Dis.Alarcón-segovia D 1980 6 223 31 - 9.
Pan-Thames Renal Research G. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. [Multicenter Study Review].Booth A. D Almond M. K Burns A Ellis P Gaskin G Neild G. H Plaisance M Pusey C. D Jayne D. R 2003 Apr;41 4 776 84 - 10.
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med.Hoffman G. S Kerr G. S Leavitt R. Y Hallahan C. W Lebovics R. S Travis W. D Rottem M Fauci A. S 1992 Mar 15;116 6 488 98 - 11.
Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed).Davies D. J Moran J. E Niall J. F Ryan G. B 1982 Aug28 Sep 4;285(6342):606. - 12.
Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody. Aust N Z J Med.Hall J. B Wadham B. M Wood C. J Ashton V Adam W. R 1984 Jun;14 3 277 8 - 13.
Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet.Van Der Woude F. J Rasmussen N Lobatto S Wiik A Permin H Van Es L. A Van Der Giessen M Van Der Hem G. K The T. H 1985 Feb 23;1 8426 425 9 - 14.
Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. J Am Soc Nephrol. [Editorial Historical Article].Falk R. J Gross W. L Guillevin L Hoffman G Jayne D. R Jennette J. C Kallenberg C. G Luqmani R Mahr A. D Matteson E. L Merkel P. A Specks U Watts R 2011 Apr;22 4 587 8 - 15.
Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Arthritis Rheum.Falk R. J Gross W. L Guillevin L Hoffman G. S Jayne D. R Jennette J. C Kallenberg C. G Luqmani R Mahr A. D Matteson E. L Merkel P. A Specks U Watts R. A 2011 Apr;63 4 863 4 - 16.
Granulomatosis with polyangiitis (Wegener’s): an alternative name for Wegener’s granulomatosis. Ann Rheum Dis.Falk R. J Gross W. L Guillevin L Hoffman G Jayne D. R Jennette J. C Kallenberg C. G Luqmani R Mahr A. D Matteson E. L Merkel P. A Specks U Watts R 2011 Apr;70(4):704. - 17.
Multistep pathogenesis of autoimmune disease. Cell.Goodnow C. C 2007 Jul 13;130 1 25 35 - 18.
Antimyeloperoxidase antibodies rapidly induce alpha-4-integrin-dependent glomerular neutrophil adhesion. Blood.Kuligowski M. P Kwan R. Y Lo C Wong C James W. G Bourges D Ooi J. D Abeynaike L. D Hall P Kitching A. R Hickey M. J 2009 Jun 18;113 25 6485 94 - 19.
Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol.Morgan M. D Harper L Williams J Savage C 2006 May;17 5 1224 34 - 20.
Participation of cell-mediated immunity in deposition of fibrin in glomerulonephritis. Lancet.Neale T. J Tipping P. G Carson S. D Holdsworth S. R 1988 Aug 20;2 8608 421 4 - 21.
Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis. J Am Soc Nephrol.Cunningham M. A Huang X. R Dowling J. P Tipping P. G Holdsworth S. R 1999 Mar;10 3 499 506 - 22.
Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int.Holdsworth S. R Kitching A. R Tipping P. G 1999 Apr;55 4 1198 216 - 23.
and autoantigen-specific Th17 cells are elevated in patients with ANCA-associated vasculitis. Nephrol Dial Transplant.Nogueira E Hamour S Sawant D Henderson S Mansfield N Chavele K. M Pusey C. D Salama A. D andSerum I. L I. L Levels 2010 Jul;25 7 2209 17 - 24.
cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol.Gan P. Y Steinmetz O. M Tan D. S O Sullivan K. M Ooi J. D Iwakura Y Kitching A. R Holdsworth S. R Th 2010 Jun;21 6 925 31 - 25.
Risks and relative risks of Wegener’s granulomatosis among close relatives of patients with the disease. Arthritis Rheum.Knight A Sandin S Askling J 2008 Jan;58 1 302 7 - 26.
The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther.Willcocks L. C Lyons P. A Rees A. J Smith K. G 2010 - 27.
Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Clin Exp Immunol.Savage C. O 2011 May;164 Suppl1 23 6 - 28.
Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hruskova Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesar V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med.Lyons P. A Rayner T. F Trivedi S Holle J. U Watts R. A Jayne D. R Baslund B Brenchley P Bruchfeld A Chaudhry A. N 2012 Jul 19;367 3 214 23 - 29.
rd, Magnuson TR, Jennette JC, Falk RJ. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest.Ciavatta D. J Yang J Preston G. A Badhwar A. K Xiao H Hewins P Nester C. M Pendergraft W. F 2010 Sep;120 9 3209 19 - 30.
Epidemiology of Wegener’s granulomatosis: Lessons from descriptive studies and analyses of genetic and environmental risk determinants. Clin Exp Rheumatol.Mahr A. D Neogi T Merkel P. A 2006 Mar-Apr;24(2 Suppl 41):S82 91 - 31.
Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol.Hogan S. L Cooper G. S Savitz D. A Nylander-french L. A Parks C. G Chin H Jennette C. E Lionaki S Jennette J. C Falk R. J 2007 Mar;2 2 290 9 - 32.
Activation-induced cell death in human peripheral blood lymphocytes after stimulation with silicate in vitro. Int J Oncol.Aikoh T Tomokuni A Matsukii T Hyodoh F Ueki H Otsuki T Ueki A 1998 Jun;12 6 1355 9 - 33.
de Lind van Wijngaarden RA van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW, Mahr AD, Niles JL, de Heer E, Bruijn JA, Bajema IM. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol.2008 Jan;3 1 237 52 - 34.
Coexistent membranous nephropathy and ANCA-positive crescentic glomerulonephritis in association with penicillamine. Nephrol Dial Transplant.Mathieson P. W Peat D. S Short A Watts R. A 1996 May;11 5 863 6 - 35.
Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. QJM.Short A. K Lockwood C. M 1995 Nov;88 11 775 83 - 36.
Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med.Tidman M Olander R Svalander C Danielsson D 1998 Aug;244 2 133 41 - 37.
Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med.Stegeman C. A Tervaert J. W Sluiter W. J Manson W. L De Jong P. E Kallenberg C. G 1994 Jan 1;120 1 12 7 - 38.
Relapses in Wegener’s granulomatosis: the role of infection. Br Med J.Pinching A. J Rees A. J Pussell B. A Lockwood C. M Mitchison R. S Peters D. K 1980 Sep 27;281 6244 836 8 - 39.
Does infection play a role in the pathogenesis of pulmonary vasculitis? Semin Respir Infect.Capizzi S. A Specks U 2003 Mar;18 1 17 22 - 40.
Serum myeloperoxidase and serum cytokines in anti-myeloperoxidase antibody-associated glomerulonephritis. Clin Nephrol.Arimura Y Minoshima S Kamiya Y Tanaka U Nakabayashi K Kitamoto K Nagasawa T Sasaki T Suzuki K 1993 Nov;40 5 256 64 - 41.
Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med.Stegeman C. A Tervaert J. W De Jong P. E Kallenberg C. G 1996 Jul 4;335 1 16 20 - 42.
Endocarditis associated with antineutrophil cytoplasmic antibodies: a case report and review of the literature. Clin Rheumatol.Chirinos J. A Corrales-medina V. F Garcia S Lichtstein D. M Bisno A. L Chakko S 2007 Apr;26 4 590 5 - 43.
Anti-MPO-ANCA-positive microscopic polyangiitis following subacute bacterial endocarditis. Clin Rheumatol.Hellmich B Ehren M Lindstaedt M Meyer M Pfohl M Schatz H 2001 20 6 441 3 - 44.
Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. Curr Top Microbiol Immunol.Oldstone M. B 2005 296 1 17 - 45.
Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med.Kain R Exner M Brandes R Ziebermayr R Cunningham D Alderson C. A Davidovits A Raab I Jahn R Ashour O Spitzauer S Sunder-plassmann G Fukuda M Klemm P Rees A. J Kerjaschki D 2008 Oct;14 10 1088 96 - 46.
rd, Preston GA, Shah RR, Tropsha A, Carter CW, Jr., Jennette JC, Falk RJ. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med.Pendergraft W. F 2004 Jan;10 1 72 9 - 47.
de Lind van Wijngaarden RA, Pusey CD. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol.Jayne D. R Gaskin G Rasmussen N Abramowicz D Ferrario F Guillevin L Mirapeix E Savage C. O Sinico R. A Stegeman C. A Westman K. W Van Der Woude F. J 2007 Jul;18 7 2180 8 - 48.
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med.Jones R. B Tervaert J. W Hauser T Luqmani R Morgan M. D Peh C. A Savage C. O Segelmark M Tesar V Van Paassen P Walsh D Walsh M Westman K Jayne D. R 2010 Jul 15;363 3 211 20 - 49.
St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med.Stone J. H Merkel P. A Spiera R Seo P Langford C. A Hoffman G. S Kallenberg C. G 2010 Jul 15;363 3 221 32 - 50.
Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int.Harper L Cockwell P Adu D Savage C. O 2001 May;59 5 1729 38 - 51.
Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int.Cockwell P Brooks C. J Adu D Savage C. O 1999 Mar;55 3 852 63 - 52.
IL-18 is upregulated in the kidney and primes neutrophil responsiveness in ANCA-associated vasculitis. Kidney Int.Hewins P Morgan M. D Holden N Neil D Williams J. M Savage C. O Harper L 2006 Feb;69 3 605 15 - 53.
Neutrophil superoxide release is required for spontaneous and FMLP-mediated but not for TNF alpha-mediated apoptosis. J Am Soc Nephrol.Kettritz R Falk R. J Jennette J. C Gaido M. L 1997 Jul;8 7 1091 100 - 54.
Antineutrophil cytoplasmic antibodies induce reactive oxygen-dependent dysregulation of primed neutrophil apoptosis and clearance by macrophages. Am J Pathol.Harper L Ren Y Savill J Adu D Savage C. O 2000 Jul;157 1 211 20 - 55.
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest.Xiao H Heeringa P Hu P Liu Z Zhao M Aratani Y Maeda N Falk R. J Jennette J. C 2002 Oct;110 7 955 63 - 56.
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol.Xiao H Heeringa P Liu Z Huugen D Hu P Maeda N Falk R. J Jennette J. C 2005 Jul;167 1 39 45 - 57.
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol.Huugen D Xiao H Van Esch A Falk R. J Peutz-kootstra C. J Buurman W. A Tervaert J. W Jennette J. C Heeringa P 2005 Jul;167 1 47 58 - 58.
AR. Intrinsic renal cell and leukocyte-derived TLR4 aggravate experimental anti-MPO glomerulonephritis. Kidney Int.Summers S. A Van Der Veen B. S O Sullivan K. M Gan P. Y Ooi J. D Heeringa P Satchell S. C Mathieson P. W Saleem M. A Visvanathan K Holdsworth S. R Kitching 2010 Dec;78 12 1263 74 - 59.
Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int.Huugen D Van Esch A Xiao H Peutz-kootstra C. J Buurman W. A Tervaert J. W Jennette J. C Heeringa P 2007 Apr;71 7 646 54 - 60.
Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood.Little M. A Smyth C. L Yadav R Ambrose L Cook H. T Nourshargh S Pusey C. D 2005 Sep 15;106 6 2050 8 - 61.
Jr., Alpers CE, Savage CO, Duffield JS. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One.Little M. A Al-ani B Ren S Al-nuaimi H Leite M 2012 e28626. - 62.
High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol.Kain R Tadema H Mckinney E. F Benharkou A Brandes R Peschel A Hubert V Feenstra T Sengolge G Stegeman C Heeringa P Lyons P. A Smith K. G Kallenberg C Rees A. J 2012 Mar;23 3 556 66 - 63.
Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol.Roth A. J Brown M. C Smith R. N Badhwar A. K Parente O Chung H Bunch D. O Mcgregor J. G Hogan S. L Hu Y Yang J. J Berg E. A Niles J Jennette J. C Preston G. A Falk R. J 2012 Mar;23 3 545 55 - 64.
Immune regulatory mechanisms in ANCA-associated vasculitides. Autoimmun Rev.Lepse N Abdulahad W. H Kallenberg C. G Heeringa P 2011 Dec;11 2 77 83 - 65.
Increased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV). Clin Exp Rheumatol.Schneeweis C Rafalowicz M Feist E Buttgereit F Rudolph P. E Burmester G. R Egerer K 2010 Jan-Feb;28(1 Suppl 57):62-6. - 66.
The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol.Stohl W Hilbert D. M 2012 Jan;30 1 69 77 - 67.
Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis. Kidney Int.Steinmetz O. M Velden J Kneissler U Marx M Klein A Helmchen U Stahl R. A Panzer U 2008 Aug;74 4 448 57 - 68.
B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity.Blair P. A Norena L. Y Flores-borja F Rawlings D. J Isenberg D. A Ehrenstein M. R Mauri C C. D19(+)C. D Hi C. D Hi 2010 Jan 29;32 1 129 40 - 69.
Successful Treatment of ANCA-Negative Wegener’s Granulomatosis with Rituximab. Int J Rheumatol.Khan A Lawson C. A Quinn M. A Isdale A. H Green M. J 2010 - 70.
Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med.Brouwer E Huitema M. G Klok P. A De Weerd H Tervaert J. W Weening J. J Kallenberg C. G 1993 Apr 1;177 4 905 14 - 71.
Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med.Kessenbrock K Krumbholz M Schonermarck U Back W Gross W. L Werb Z Grone H. J Brinkmann V Jenne D. E 2009 Jun;15 6 623 5 - 72.
Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. J Am Soc Nephrol.Ruth A. J Kitching A. R Kwan R. Y Odobasic D Ooi J. D Timoshanko J. R Hickey M. J Holdsworth S. R 2006 Jul;17 7 1940 9 - 73.
Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener’s granulomatosis and clinically related disorders. Clin Exp Immunol.Brouwer E Tervaert J. W Horst G Huitema M. G Van Der Giessen M Limburg P. C Kallenberg C. G 1991 Mar;83 3 379 86 - 74.
T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol.Griffith M. E Coulthart A Pusey C. D 1996 Feb;103 2 253 8 - 75.
Persistent T-cell activation and clinical correlations in patients with ANCA-associated systemic vasculitis. Nephrol Dial Transplant.Marinaki S Kalsch A. I Grimminger P Breedijk A Birck R Schmitt W. H Weiss C Van Der Woude F. J Yard B. A 2006 Jul;21 7 1825 32 - 76.
and T-cell activation in Wegener’s granulomatosis. J Allergy Clin Immunol.Popa E. R Stegeman C. A Bos N. A Kallenberg C. G Tervaert J. W Differential B 1999 May;103(5 Pt 1):885-94. - 77.
Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int.Schmitt W. H Hagen E. C Neumann I Nowack R Flores-suarez L. F Van Der Woude F. J 2004 Apr;65 4 1440 8 - 78.
In vitro production of myeloperoxidase anti-neutrophil cytoplasmic antibody and establishment of Th1-type T cell lines from peripheral blood lymphocytes of patients. Clin Exp Rheumatol.Yoshida M Iwahori T Nakabayashi I Akashi M Watanabe T Yoshikawa N 2005 Mar-Apr;23 2 227 30 - 79.
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol.Park H Li Z Yang X. O Chang S. H Nurieva R Wang Y. H Wang Y Hood L Zhu Z Tian Q Dong C 2005 Nov;6 11 1133 41 - 80.
Skewed distribution of Th17 lymphocytes in patients with Wegener’s granulomatosis in remission. Arthritis Rheum.Abdulahad W. H Stegeman C. A Limburg P. C Kallenberg C. G 2008 Jul;58 7 2196 205 - 81.
expression in human ANCA-associated glomerulonephritis. Am J Physiol Renal Physiol.Velden J Paust H. J Hoxha E Turner J. E Steinmetz O. M Wolf G Jabs W. J Ozcan F Beige J Heering P. J Schroder S Kneissler U Disteldorf E Mittrucker H. W Stahl R. A Helmchen U Panzer U Renal I. L 2012 Jun 15;302(12):F1663 73 - 82.
Toll-like receptor 2 induces Th17 myeloperoxidase autoimmunity while Toll-like receptor 9 drives Th1 autoimmunity in murine vasculitis. Arthritis Rheum.Summers S. A Steinmetz O. M Gan P. Y Ooi J. D Odobasic D Kitching A. R Holdsworth S. R 2011 Apr;63 4 1124 35 - 83.
The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis. Proc Natl Acad Sci U S A.Ooi J. D Chang J Hickey M. J Borza D. B Fugger L Holdsworth S. R Kitching A. R 2012 Sep 5. - 84.
different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol.Mosmann T. R Coffman R. L T. H1 a. n. d T. H Cells 1989 7 145 73 - 85.
Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity.Yao Z Fanslow W. C Seldin M. F Rousseau A. M Painter S. L Comeau M. R Cohen J. I Spriggs M. K 1995 Dec;3 6 811 21 - 86.
effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol.Harrington L. E Hatton R. D Mangan P. R Turner H Murphy T. L Murphy K. M Weaver C. T Interleukin 17-producing C. D 2005 Nov;6 11 1123 32 - 87.
Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. J Immunol.Yang J. Q Singh A. K Wilson M. T Satoh M Stanic A. K Park J. J Hong S Gadola S. D Mizutani A Kakumanu S. R Reeves W. H Cerundolo V Joyce S Van Kaer L Singh R. R 2003 Aug 15;171 4 2142 53 - 88.
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell.Ivanov I. I Mckenzie B. S Zhou L Tadokoro C. E Lepelley A Lafaille J. J Cua D. J Littman D. R 2006 Sep 22;126 6 1121 33 - 89.
T cell population that induces autoimmune inflammation. J Exp Med.Langrish C. L Chen Y Blumenschein W. M Mattson J Basham B Sedgwick J. D Mcclanahan T Kastelein R. A Cua D. J I. L Drives a Pathogenic 2005 Jan 17;201 2 233 40 - 90.
CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature.Mangan P. R Harrington L. E O Quinn D. B Helms W. S Bullard D. C Elson C. O Hatton R. D Wahl S. M Schoeb T. R Weaver 2006 May 11;441 7090 231 4 - 91.
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity.Veldhoen M Hocking R. J Atkins C. J Locksley R. M Stockinger B 2006 Feb;24 2 179 89 - 92.
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature.Bettelli E Carrier Y Gao W Korn T Strom T. B Oukka M Weiner H. L Kuchroo V. K 2006 May 11;441 7090 235 8 - 93.
Induction and effector functions of T(H)17 cells. Nature.Bettelli E Korn T Oukka M Kuchroo V. K 2008 Jun 19;453 7198 1051 7 - 94.
IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature.Korn T Bettelli E Gao W Awasthi A Jager A Strom T. B Oukka M Kuchroo V. K 2007 Jul 26;448 7152 484 7 - 95.
Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature.Nurieva R Yang X. O Martinez G Zhang Y Panopoulos A. D Ma L Schluns K Tian Q Watowich S. S Jetten A. M Dong C 2007 Jul 26;448 7152 480 3 - 96.
T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol.Zhou L Ivanov I. I Spolski R Min R Shenderov K Egawa T Levy D. E Leonard W. J Littman D. R I. L Programs 2007 Sep;8 9 967 74 - 97.
Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. J Clin Invest.Becher B Durell B. G Noelle R. J 2002 Aug;110 4 493 7 - 98.
IL-12Gran B Zhang G. X Yu S Li J Chen X. H Ventura E. S Kamoun M Rostami A 35 mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol.2002 Dec 15;169(12):7104-10. - 99.
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature.Cua D. J Sherlock J Chen Y Murphy C. A Joyce B Seymour B Lucian L To W Kwan S Churakova T Zurawski S Wiekowski M Lira S. A Gorman D Kastelein R. A Sedgwick J. D 2003 Feb 13;421 6924 744 8 - 100.
IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol.Komiyama Y Nakae S Matsuki T Nambu A Ishigame H Kakuta S Sudo K Iwakura Y 2006 Jul 1;177 1 566 73 - 101.
Gene microarray analysis of multiple sclerosis lesions. Trends Mol Med.Lock C. B Heller R. A 2003 Dec;9 12 535 41 - 102.
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum.Chabaud M Durand J. M Buchs N Fossiez F Page G Frappart L Miossec P 1999 May;42 5 963 70 - 103.
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med.Murphy C. A Langrish C. L Chen Y Blumenschein W Mcclanahan T Kastelein R. A Sedgwick J. D Cua D. J 2003 Dec 15;198 12 1951 7 - 104.
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol.Nakae S Nambu A Sudo K Iwakura Y 2003 Dec 1;171 11 6173 7 - 105.
Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology.Elson C. O Cong Y Weaver C. T Schoeb T. R Mcclanahan T. K Fick R. B Kastelein R. A 2007 Jun;132 7 2359 70 - 106.
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science.Duerr R. H Taylor K. D Brant S. R Rioux J. D Silverberg M. S Daly M. J Steinhart A. H Abraham C Regueiro M Griffiths A Dassopoulos T Bitton A Yang H Targan S Datta L. W Kistner E. O Schumm L. P Lee A. T Gregersen P. K Barmada M. M Rotter J. I Nicolae D. L Cho J. H 2006 Dec 1;314 5804 1461 3 - 107.
A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med.Krueger G. G Langley R. G Leonardi C Yeilding N Guzzo C Wang Y Dooley L. T Lebwohl M 2007 Feb 8;356 6 580 92 - 108.
de Waal Malefyt R. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol.Wilson N. J Boniface K Chan J. R Mckenzie B. S Blumenschein W. M Mattson J. D Basham B Smith K Chen T Morel F Lecron J. C Kastelein R. A Cua D. J Mcclanahan T. K Bowman E. P 2007 Sep;8 9 950 7 - 109.
IL-12, directs autoimmunity to the Goodpasture antigen. J Am Soc Nephrol.Ooi J. D Phoon R. K Holdsworth S. R Kitching A. R I. L Not 2009 May;20 5 980 9 - 110.
Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol.Paust H. J Turner J. E Steinmetz O. M Peters A Heymann F Holscher C Wolf G Kurts C Mittrucker H. W Stahl R. A Panzer U The I. L 2009 May;20 5 969 79 - 111.
The Th17-Defining Transcription Factor ROR{gamma}t Promotes Glomerulonephritis. J Am Soc Nephrol.Steinmetz O. M Summers S. A Gan P. Y Semple T Holdsworth S. R Kitching A. R 2011 Mar;22 3 472 83 - 112.
Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol.Summers S. A Steinmetz O. M Li M Kausman J. Y Semple T Edgtton K. L Borza D. B Braley H Holdsworth S. R Kitching A. R 2009 Dec;20 12 2518 24 - 113.
The emergence of TH17 cells as effectors of renal injury. J Am Soc Nephrol.Kitching A. R Holdsworth S. R 2011 Feb;22 2 235 8 - 114.
The Th17 immune response in renal inflammation. Kidney Int.Turner J. E Paust H. J Steinmetz O. M Panzer U 2010 Jun;77 12 1070 5 - 115.
Etanercept plus standard therapy for Wegener’s granulomatosis N Engl J Med.2005 Jan 27;352 4 351 61 - 116.
effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum.Abdulahad W. H Kallenberg C. G Limburg P. C Stegeman C. A Urinary C. D 2009 Sep;60 9 2830 8 - 117.
Excessive interleukin-15 transpresentation endows NKG2D+CD4+ T cells with innate-like capacity to lyse vascular endothelium in granulomatosis with polyangiitis (Wegener’s). Arthritis Rheum.De Menthon M Lambert M Guiard E Tognarelli S Bienvenu B Karras A Guillevin L Caillat-zucman S 2011 Jul;63 7 2116 26 - 118.
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med.Mckinney E. F Lyons P. A Carr E. J Hollis J. L Jayne D. R Willcocks L. C Koukoulaki M Brazma A Jovanovic V Kemeny D. M Pollard A. J Macary P. A Chaudhry A. N Smith K. G 2010 May;16 5 586 91 p following 91. - 119.
Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture’s (anti-GBM) disease. Kidney Int.Salama A. D Chaudhry A. N Holthaus K. A Mosley K Kalluri R Sayegh M. H Lechler R. I Pusey C. D Lightstone L 2003 Nov;64 5 1685 94 - 120.
Doornbos-van der Meer B, Limburg PC, Kallenberg CG. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener’s granulomatosis in remission. Arthritis Rheum.Abdulahad W. H Stegeman C. A Van Der Geld Y. M 2007 Jun;56 6 2080 91 - 121.
Regulation of myeloperoxidase-specific T cell responses during disease remission in antineutrophil cytoplasmic antibody-associated vasculitis: the role of Treg cells and tryptophan degradation. Arthritis Rheum.Chavele K. M Shukla D Keteepe-arachi T Seidel J. A Fuchs D Pusey C. D Salama A. D 2010 May;62 5 1539 48 - 122.
Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med.Gilligan H. M Bredy B Brady H. R Hebert M. J Slayter H. S Xu Y Rauch J Shia M. A Koh J. S Levine J. S 1996 Dec 1;184 6 2231 41 - 123.
Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. Clin Exp Immunol.Yang J. J Tuttle R. H Hogan S. L Taylor J. G Phillips B. D Falk R. J Jennette J. C 2000 Jul;121 1 165 72 - 124.
Neutrophil extracellular traps kill bacteria. Science.Brinkmann V Reichard U Goosmann C Fauler B Uhlemann Y Weiss D. S Weinrauch Y Zychlinsky A 2004 Mar 5;303 5663 1532 5 - 125.
Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med.Lande R Ganguly D Facchinetti V Frasca L Conrad C Gregorio J Meller S Chamilos G Sebasigari R Riccieri V Bassett R Amuro H Fukuhara S Ito T Liu Y. J Gilliet M 2011 Mar 9;3(73):73ra19. - 126.
Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med.Garcia-romo G. S Caielli S Vega B Connolly J Allantaz F Xu Z Punaro M Baisch J Guiducci C Coffman R. L Barrat F. J Banchereau J Pascual V 2011 Mar 9;3(73):73ra20. - 127.
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol.Villanueva E Yalavarthi S Berthier C. C Hodgin J. B Khandpur R Lin A. M Rubin C. J Zhao W Olsen S. H Klinker M Shealy D Denny M. F Plumas J Chaperot L Kretzler M Bruce A. T Kaplan M. J 2011 Jul 1;187 1 538 52 - 128.
Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells towards ANCA induction and associated autoimmunity. Blood.Sangaletti S Tripodo C Chiodoni C Guarnotta C Cappetti B Casalini P Piconese S Parenza M Guiducci C Vitali C Colombo M. P 2012 Aug 29. - 129.
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol.Mulder A. H Heeringa P Brouwer E Limburg P. C Kallenberg C. G 1994 Nov;98 2 270 8 - 130.
Therapeutic effect of anti-TNF-alpha antibodies in an experimental model of anti-neutrophil cytoplasm antibody-associated systemic vasculitis. J Am Soc Nephrol.Little M. A Bhangal G Smyth C. L Nakada M. T Cook H. T Nourshargh S Pusey C. D 2006 Jan;17 1 160 9 - 131.
Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology (Oxford).Lamprecht P Voswinkel J Lilienthal T Nolle B Heller M Gross W. L Gause A 2002 Nov;41 11 1303 7 - 132.
Le Hello C, Guillevin L. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford).Bartolucci P Ramanoelina J Cohen P Mahr A Godmer P 2002 Oct;41 10 1126 32 - 133.
Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract.Morgan M. D Drayson M. T Savage C. O Harper L 2011 c89 97 - 134.
Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant.Laurino S Chaudhry A Booth A Conte G Jayne D 2010 Oct;25 10 3307 14 - 135.
IL-1 beta production by human polymorphonuclear leucocytes stimulated by anti-neutrophil cytoplasmic autoantibodies: relevance to systemic vasculitis. Clin Exp Immunol.Brooks C. J King W. J Radford D. J Adu D Mcgrath M Savage C. O 1996 Nov;106 2 273 9 - 136.
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med.Lachmann H. J Kone-paut I Kuemmerle-deschner J. B Leslie K. S Hachulla E Quartier P Gitton X Widmer A Patel N Hawkins P. N 2009 Jun 4;360 23 2416 25 - 137.
Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18. J Am Soc Nephrol.Hewins P Williams J. M Wakelam M. J Savage C. O 2004 Mar;15 3 796 808 - 138.
Phosphatidylinositol 3-kinase controls antineutrophil cytoplasmic antibodies-induced respiratory burst in human neutrophils. J Am Soc Nephrol.Kettritz R Choi M Butt W Rane M Rolle S Luft F. C Klein J. B 2002 Jul;13 7 1740 9 - 139.
Characterization of the regulation and functional consequences ofWilliams J. M Savage C. O 21ras activation in neutrophils by antineutrophil cytoplasm antibodies. J Am Soc Nephrol.2005 Jan;16(1):90-6. - 140.
Deal watch: high hopes for oral SYK inhibitor in rheumatoid arthritis. Nat Rev Drug Discov.Flight M. H 2012 Jan;11(1):10. - 141.
Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS). Clin Exp Immunol.Katzav A Kloog Y Korczyn A. D Niv H Karussis D. M Wang N Rabinowitz R Blank M Shoenfeld Y Chapman J 2001 Dec;126 3 570 7 - 142.
Endothelium-Neutrophil Interactions in ANCA-Associated Diseases. J Am Soc Nephrol.Halbwachs L Lesavre P 2012 Sep;23 9 1449 61 - 143.
Anti-neutrophil cytoplasm antibodies (ANCA) increase neutrophil adhesion to cultured human endothelium. Adv Exp Med Biol.Keogan M. T Rifkin I Ronda N Lockwood C. M Brown D. L 1993 336 115 9 - 144.
Antimyeloperoxidase antibodies induce neutrophil adherence to cultured human endothelial cells. Ren Fail.Ewert B. H Becker M. E Jennette J. C Falk R. J 1995 Mar;17 2 125 33 - 145.
Up-regulation of the granulocyte adhesion molecule Mac-1 by autoantibodies in autoimmune vasculitis. Clin Exp Immunol.Johnson P. A Alexander H. D Mcmillan S. A Maxwell A. P 1997 Mar;107 3 513 9 - 146.
ANCA induces beta2 integrin and CXC chemokine-dependent neutrophil-endothelial cell interactions that mimic those of highly cytokine-activated endothelium. J Leukoc Biol.Calderwood J. W Williams J. M Morgan M. D Nash G. B Savage C. O 2005 Jan;77 1 33 43 - 147.
Circulating leukocyte integrin expression in Wegener’s granulomatosis. J Am Soc Nephrol.Haller H Eichhorn J Pieper K Gobel U Luft F. C 1996 Jan;7 1 40 8 - 148.
Renal expression of adhesion molecules in anca-associated disease. J Clin Immunol.Arrizabalaga P Sole M Abellana R Ascaso C 2008 Sep;28 5 411 9 - 149.
Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int.Ewert B. H Jennette J. C Falk R. J 1992 Feb;41 2 375 83 - 150.
Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol.Savage C. O Pottinger B. E Gaskin G Pusey C. D Pearson J. D 1992 Aug;141 2 335 42 - 151.
Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol.Porges A. J Redecha P. B Kimberly W. T Csernok E Gross W. L Kimberly R. P 1994 Aug 1;153 3 1271 80 - 152.
Effect of tumor necrosis factor-induced integrin activation on Fc gamma receptor II-mediated signal transduction: relevance for activation of neutrophils by anti-proteinase 3 or anti-myeloperoxidase antibodies. Blood.Reumaux D Vossebeld P. J Roos D Verhoeven A. J 1995 Oct 15;86 8 3189 95 - 153.
Diagnostic role of endothelial microparticles in vasculitis. Rheumatology (Oxford).Erdbruegger U Grossheim M Hertel B Wyss K Kirsch T Woywodt A Haller H Haubitz M 2008 Dec;47 12 1820 5 - 154.
Circulating angiopoietin-2 is a marker and potential mediator of endothelial cell detachment in ANCA-associated vasculitis with renal involvement. Nephrol Dial Transplant.Kumpers P Hellpap J David S Horn R Leitolf H Haller H Haubitz M 2009 Jun;24 6 1845 50 - 155.
Vascular endothelial damage and repair in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum.De Groot K Goldberg C Bahlmann F. H Woywodt A Haller H Fliser D Haubitz M 2007 Nov;56 11 3847 53 - 156.
Circulating endothelial progenitor cells in patients with ANCA-associated vasculitis. Kidney Blood Press Res.Zavada J Kideryova L Pytlik R Vankova Z Tesar V 2008 31 4 247 54 - 157.
Internalization of proteinase 3 is concomitant with endothelial cell apoptosis and internalization of myeloperoxidase with generation of intracellular oxidants. Am J Pathol.Yang J. J Preston G. A Pendergraft W. F Segelmark M Heeringa P Hogan S. L Jennette J. C Falk R. J 2001 Feb;158 2 581 92 - 158.
Leukocyte recruitment to the inflamed glomerulus: a critical role for platelet-derived P-selectin in the absence of rolling. J Immunol.Kuligowski M. P Kitching A. R Hickey M. J 2006 Jun 1;176 11 6991 9 - 159.
Platelet recruitment to the inflamed glomerulus occurs via an alphaIIbbeta3/GPVI-dependent pathway. Am J Pathol.Devi S Kuligowski M. P Kwan R. Y Westein E Jackson S. P Kitching A. R Hickey M. J 2010 Sep;177 3 1131 42 - 160.
Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum.Radford D. J Savage C. O Nash G. B 2000 Jun;43 6 1337 45 - 161.
Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo. J Am Soc Nephrol.Nolan S. L Kalia N Nash G. B Kamel D Heeringa P Savage C. O 2008 May;19 5 973 84 - 162.
Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils. Exp Cell Res.Gasser O Hess C Miot S Deon C Sanchez J. C Schifferli J. A 2003 May 1;285 2 243 57 - 163.
Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol.Hong Y Eleftheriou D Hussain A. A Price-kuehne F. E Savage C. O Jayne D Little M. A Salama A. D Klein N. J Brogan P. A 2012 Jan;23 1 49 62 - 164.
Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev.Medzhitov R Janeway C 2000 Feb;173 89 97 - 165.
The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr Mol Med.Li M Zhou Y Feng G Su S. B 2009 Apr;9 3 365 74 - 166.
Tracking the toll of kidney disease. J Am Soc Nephrol.Shirali A. C Goldstein D. R 2008 Aug;19 8 1444 50 - 167.
TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest.Wu H Chen G Wyburn K. R Yin J Bertolino P Eris J. M Alexander S. I Sharland A. F Chadban S. J 2007 Oct;117 10 2847 59 - 168.
and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. J Autoimmun.Summers S. A Hoi A Steinmetz O. M O Sullivan K. M Ooi J. D Odobasic D Akira S Kitching A. R Holdsworth S. R Tlr 2010 Dec;35 4 291 8 - 169.
Toll Like Receptor 9 Ligation Enhances Experimental Crescentic Glomerulonephritis J Am Soc Nephrol AbstractsSummers S. A Steinmetz O. M Kitching A. R Holdsworth S. R 20 TH-PO824.2009 - 170.
CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol.Hurtado P. R Jeffs L Nitschke J Patel M Sarvestani G Cassidy J Hissaria P Gillis D Peh C. A 2008 - 171.
Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology (Oxford).Tadema H Abdulahad W. H Lepse N Stegeman C. A Kallenberg C. G Heeringa P 2010 Dec 11. - 172.
Increased expression of Toll-like receptors by monocytes and natural killer cells in ANCA-associated vasculitis. PLoS One.Tadema H Abdulahad W. H Stegeman C. A Kallenberg C. G Heeringa P 2011 e24315. - 173.
Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. Lupus.Papadimitraki E. D Tzardi M Bertsias G Sotsiou E Boumpas D. T 2009 Aug;18 9 831 5 - 174.
Expression of Toll-like receptor 9 in renal podocytes in childhood-onset active and inactive lupus nephritis. Nephrol Dial Transplant.Machida H Ito S Hirose T Takeshita F Oshiro H Nakamura T Mori M Inayama Y Yan K Kobayashi N Yokota S 2010 Aug;25 8 2530 537 - 175.
Protein level expression of Toll-like receptors 2, 4 and 9 in renal disease. Nephrol Dial Transplant.Batsford S Duermueller U Seemayer C Mueller C Hopfer H Mihatsch M 2011 Apr;26 4 1413 6 - 176.
Antibodies to proteinase 3 prime human oral, lung, and kidney epithelial cells to secrete proinflammatory cytokines upon stimulation with agonists to various Toll-like receptors, NOD1, and NOD2. Clin Vaccine Immunol.Uehara A Hirabayashi Y Takada H 2008 Jul;15 7 1060 6 - 177.
Complement regulators and inhibitory proteins. Nat Rev Immunol.Zipfel P. F Skerka C 2009 Oct;9 10 729 40 - 178.
Complement in human diseases: Lessons from complement deficiencies. Mol Immunol.Botto M Kirschfink M Macor P Pickering M. C Wurzner R Tedesco F 2009 Sep;46 14 2774 83 - 179.
Molecular intercommunication between the complement and coagulation systems. J Immunol.Amara U Flierl M. A Rittirsch D Klos A Chen H Acker B Bruckner U. B Nilsson B Gebhard F Lambris J. D Huber-lang M 2010 Nov 1;185 9 5628 36 - 180.
Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int.Haas M Eustace J. A 2004 Jun;65 6 2145 52 - 181.
Detection of immune deposits in skin lesions of patients with Wegener’s granulomatosis. Ann Rheum Dis.Brons R. H De Jong M. C De Boer N. K Stegeman C. A Kallenberg C. G Tervaert J. W 2001 Dec;60 12 1097 102 - 182.
Wegener’s granulomatosis: observations on 18 patients with severe renal disease. Q J Med.Pinching A. J Lockwood C. M Pussell B. A Rees A. J Sweny P Evans D. J Bowley N Peters D. K 1983 Autumn;52 208 435 60 - 183.
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol.Xiao H Schreiber A Heeringa P Falk R. J Jennette J. C 2007 Jan;170 1 52 64 - 184.
a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol.Schreiber A Xiao H Jennette J. C Schneider W Luft F. C Kettritz R. C 2009 Feb;20 2 289 98 - 185.
MAPK, ERK and PI3K signaling pathways are involved in C5a-primed neutrophils for ANCA-mediated activation. PLoS One.Hao J Meng L. Q Xu P. C Chen M Zhao M. H. p 2012 e38317. - 186.
a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther.Yuan J Gou S. J Huang J Hao J Chen M Zhao M. H. C 2012 Jun 12;14(3):R140. - 187.
Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med.Ludewig B Odermatt B Landmann S Hengartner H Zinkernagel R. M 1998 Oct 19;188 8 1493 501 - 188.
Regulation of the immune response by antigen. Science.Zinkernagel R. M Hengartner H 2001 Jul 13;293 5528 251 3 - 189.
Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway. Blood.Csernok E Ai M Gross W. L Wicklein D Petersen A Lindner B Lamprecht P Holle J. U Hellmich B 2006 Jun 1;107 11 4440 8 - 190.
Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus. Autoimmun Rev.Chan V. S Nie Y. J Shen N Yan S Mok M. Y Lau C. S 2012 Mar 20. - 191.
Dendritic cells in renal biopsies of patients with ANCA-associated vasculitis. Nephrol Dial Transplant.Wilde B Van Paassen P Damoiseaux J Heerings-rewinkel P Van Rie H Witzke O Tervaert J. W 2009 Jul;24 7 2151 6 - 192.
MAPK isoform expression and activation in antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: role ofPolzer K Soleiman A Baum W Axmann R Distler J Redlich K Kilian A Kronke G Schett G Zwerina J Selective p 38MAPKalpha Ann Rheum Dis.2008 May;67(5):602-8. - 193.
de Lind van Wijngaarden RA Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noel LH, Ferrario F, Waldherr R, Hagen EC, Bruijn JA, Bajema IM. Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol.2006 Aug;17 8 2264 74 - 194.
Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest.Bonventre J. V Yang L 2011 Nov;121 11 4210 21 - 195.
The Duffy antigen receptor for chemokines is up-regulated during acute renal transplant rejection and crescentic glomerulonephritis. Kidney Int.Segerer S Regele H Mac K. M Kain R Cartron J. P Colin Y Kerjaschki D Schlondorff D 2000 Oct;58 4 1546 56 - 196.
High endothelial venule-like vessels in the interstitial lesions of human glomerulonephritis. Am J Nephrol.Takaeda M Yokoyama H Segawa-takaeda C Wada T Kobayashi K 2002 Jan-Feb;22 1 48 57